CN Patent

CN107641123A — 一种依鲁替尼及其关键中间体的制备新方法

Assigned to NANJING YIHUA PHARMACEUTICAL CO Ltd · Expires 2018-01-30 · 8y expired

What this patent protects

本发明涉及一种依鲁替尼及其关键中间体的制备新方法，避免了现有合成工艺较为严苛的反应条件，以及价格昂贵的起始物料和试剂。采用一锅化法反应合成关键中间体，简化了较为繁琐的后处理操作，降低了成本。获得的中间体纯度在99%以上，收率较高，操作简单，适于工业化生产。

USPTO Abstract

本发明涉及一种依鲁替尼及其关键中间体的制备新方法，避免了现有合成工艺较为严苛的反应条件，以及价格昂贵的起始物料和试剂。采用一锅化法反应合成关键中间体，简化了较为繁琐的后处理操作，降低了成本。获得的中间体纯度在99%以上，收率较高，操作简单，适于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN107641123A
Jurisdiction
CN
Classification
—
Expires
2018-01-30
Drug substance claim
No
Drug product claim
No
Assignee
NANJING YIHUA PHARMACEUTICAL CO Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.